# HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Source: https://onco.cc/trials/nct07240766/  
OnCo record `nct07240766` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nimotuzumab in pancreatic cancer, run by Zhejiang University, now recruiting.

## Summary

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation is a phase 2, interventional study registered as NCT07240766 by Zhejiang University, with a registry enrolment figure of 40 participants, started 2026-02-15 and due to reach its primary completion in 2027-05-15. Interventions recorded: HRS-4642+AG+Nimotuzumab. Conditions listed: Borderline Resectable Pancreatic Adenocarcinoma. Primary outcome: 12-month Event-Free Survival (EFS) rate. Pancreatic eligibility wording from the registry: "* Histopathologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07240766
- Phase: 2
- Setting: Phase II Study of HRS-4642 in Combination With Nimotuzumab and Chemotherapy for Subjects With Borderline Resectable Pancreatic Cancer With KRAS G12D Mutation
- Sponsor: Zhejiang University
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07240766: https://clinicaltrials.gov/study/NCT07240766

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- drugs: [Nimotuzumab](https://onco.cc/drugs/nimotuzumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07240766.json